

First Name	Last Name	City	Hospital / University	Country	Disclosures
Julio	Delgado	Barcelona	Hospital Clinic de Barcelona	Spain	I have no conflicts of interest from Pharmaceutical companies. I am employed by Hospital Clinic de Barcelona, which is the owner of several academic CART-cell products
Abraham	Avigdor	Tel-Hashomer	Sheba Medical Center	Israel	Advisory board: Roche, Takeda, BMS, Novartis, Gilead, Janssen
Alejandro	Madrigal	London	UCL, Cancer Institute	United Kingdom	none
Alexandros	Rampotas	London	University College London Hospital NHS Foundation Trust	United Kingdom	Gilead: Conference fees
Ana Maria	Sureda Balari	Barcelona	Institut Català d'Oncologia - Hospital Duran i Reynals	Spain	Takeda, BMS/Celgene, MSD, Janssen, Amgen, Novartis, Gilead Kite, Sanofi, Roche, Alexion
André Charles	BARUCHEL	Paris	Robert Debré University Hospital/Université Paris Cité	France	Servier Jazz Clinigen Novartis Sanofi Astra Zeneca
Andreas	Mackensen	Erlangen	University Hospital of Erlangen	Germany	none
Anna	Dodero	Milan	Fondazione IRCCS Istituto Nazionale dei Tumori	Italy	no
Annette	Künkele	Berlin	Charité - University Hospital Berlin	Germany	none
Antonia	Mueller	Vienna	Medical University of Vienna	Austria	Consulting and ad boards for Novartis, Kite/Gilead, BMS, Janssen, Vertex
Audrey	Grain	Nantes	University Hospital of Nantes	France	none
Bertram	Glass	Berlin	Helios Klinik Berlin-Buch	Germany	Roche, BMS, Gilead, Novartis, Miltenyi, Janssen, Abbvie, Jazz
Bianca	Santomasso	New York	Memorial Sloan Kettering Cancer Center	United States of America	Consulting: Legend, Celgene/BMS, Kite/Gilead, Incyte, Pfizer; Advisory board: Janssen, In8bio
Candice	Hendricks	Pretoria	University of Pretoria	South Africa	I received travel support from the EBMT to attend the 2023 CAR-T (Rotterdam) and Transplant and Cellular therapy meeting (Barcelona)
Carlos Jose	Fernandez de Larrea Rodriguez	Barcelona	Hospital Clinic de Barcelona	Spain	Advisory boards: Janssen, BMS, Amgen, Pfizer, Sanofi; Honoraria: Amgen, Janssen, BMS, GSK, Sanofi; Grants: BMS, Janssen, Amgen, GSK
Carmen	Sanges	Würzburg	university clinic würzburg	Germany	none
Caroline	Pothet	Amsterdam	European Medicines Agency	Netherlands	I have no conflict of interest; in addition, I need confirmation that the meeting organiser hereby declares that any travel and accommodation costs and expenses concerning my participation that will be directly borne by the meeting organizer will not be linked to an individual pharmaceutical company."
Charalampia	Kyriakou	London	University College London Hospital NHS Foundation Trust	United Kingdom	No relevant conflict of interest
Christian	Chabannon	(en blanco)	Institut Paoli-Calmettes Comprehensive Cancer Center	Marseille	Honorarium: Bellicum Pharmaceuticals, BMS, Janssen Pharmaceuticals, Jazz, Kite/Gilead, Miltenyi biotec, Novartis - Consultant: Bellicum Pharmaceuticals, BMS, Janssen Pharmaceuticals, Kite/Gilead - Other Financial or Material Support: BMS, Kite/Gilead - Speakers' Bureau: BMS, Kite/Gilead, Miltenyi biotec, Novartis
Concetta	Quintarelli	Rome	Bambino Gesù Children's Hospital	Italy	No relevant disclosures
Corina	Amor Vegas	Cold Spring Harbor	Cold Spring Harbor Laboratory	United States of America	Patents on senolytic CAR T cells and consultant for FATE therapeutics.
Dalia	Dawoud	London	National Institute for Health and Care Excellence (NICE)	United Kingdom	none
Daniel	Sarmito	Madrid	(en blanco)	Spain	(en blanco)
Dirk Hans	Busch	Munich	Technical University Munich; Insitute for Medical Microbiology, Immunology and Hygiene	Germany	(en blanco)
Edwin	Bremer	Groningen	University Medical Center Groningen	The Netherlands	none
Eleni	Gavrilaki	Thessaloniki	Aristotle University of Thessaloniki	Greece	EG has received honoraria from AstraZeneca, Gilead, Omeros, Sanofi, Sobi, and research funding from Gilead and Jazz Pharmaceuticals.
Erik	Aerts	Zürich	University Hospital Zürich	Switzerland	no disclosures
Ernesta Paola	Neri	Calgary	University of Calgary	Canada	Speaker bureau/honoraria: Bristol-Myers Squibb, Janssen, Sanofi, Pfizer Consulting fees: BMS, Janssen, Sanofi
Fabio	Ciceri	Milano	IRCCS San Raffaele Scientific Institute	Italy	no
Frederick W.	Thielen	Rotterdam	Erasmus University Rotterdam	The Netherlands	Previous and ongoing research I was involved in, was or is partly funded by Celgene B.V., NICE (UK National Institute for Health and Care Excellence), CADTH (Canadian Agency for Drugs and Technologies in Health), the Dutch Ministry of Health, Welfare and Sport, the Dutch Health Care Institute, and the European Haematology Association. Since 2019, I teach Statistical Programming & Data Science in R, at TriData, an institute for applied statistics and data analysis. In 2020, I consulted AstraZeneca on a reimbursement dossier for a treatment and disease indication unrelated to this presentation. ESHPM was reimbursed for my time spent. In 2021, I consulted Optimax Access, a UK-based HEOR consultancy. In 2022, I consulted Dark Peak Analytics, a UK-based consultancy for HE and data science, specialised in R Shiny. In 2023, following my attendance at the ISPOR conference in Copenhagen, I gave a keynote presentation to the market access managers of Boehringer-Ingelheim. The company covered the fees of adjusting my initial flight home to a later time on the same day. Prior to my presentation, I also invited to take lunch from the hotel's buffet.
Geertruida Cornelia Marie (Trudy)	Straetemans	Utrecht	University Medical Center Utrecht	The Netherlands	none
Gérard	de Pourvoirville	Paris	ESSEC Business School	France	none
Gonzalo	Calvo Rojas	Barcelona	Hospital Clinic de Barcelona	Spain	(en blanco)
Halvard Bjoern	Boenig	Frankfurt a.M.	Goethe University	Germany	Speaker's bureau and advisory committee: BMS, Novartis, Miltenyi Biotech, Terumo BCT, Boehringer Ingelheim, NMDP, Medac. Licensing fees and royalties: Medac. Stock: Healthineers.
He	Huang	Hangzhou	The First Affiliated Hospital, Zhejiang University School of Medicine	China	no

First Name	Last Name	City	Hospital / University	Country	Disclosures
Hermann	Einsele	Wurzburg	University Hospital Wurzburg	Germany	Consulting or Advisory Role: BMS/Celgene, Janssen, Amgen, Takeda, Sanofi, GSK, Novartis Research Funding; BMS/Celgene, Janssen, Amgen, GSK, Sanofi Honoraria: BMS/Celgene, Janssen, Amgen, Takeda, Sanofi, GSK, Novartis Travel Support: BMS/Celgene, Janssen, Amgen, Takeda, Novartis, Sanofi
Ibrahim	Yakoub-Agha	Lille	CHU de Lille	France	Honorarium Novartis, Kite, BMS, Miltenyi Biomedecine
Jaap	van Doesum	Groningen	University Medical Center Groningen	The Netherlands	none
James F.	Howard Jr	Chapel Hill	The University of North Carolina at Chapel Hill	United States of America	James F Howard Jr: Research funding (paid to institution) from Alexion AstraZeneca Rare Disease, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, MGFA, Muscular Dystrophy Association, NIH, PCORI, Ra Pharmaceuticals/UCB Bioscience, and Takeda Pharmaceuticals; honoraria/consulting fees from AcademicCME, Alexion AstraZeneca Rare Disease, argenx, Biologix Pharma, F. Hoffmann-LaRoche Ltd, Horizon Therapeutics plc, Medscape CME, Merck EMB Serono, NMD Pharma, Novartis Pharma, PeerView CME, PlatformQ CME, Regeneron Pharmaceuticals, Sanofi US, and Zai Labs; non-financial support from Alexion AstraZeneca Rare Disease, argenx, Cartesian Therapeutics, Toleranzia AB, UCB Bioscience and Zai Labs.
Jana	Pelouchova	Prague	Diagnoza leukemie, patient society	Czech Republic	Novartis and Servier advisory boards
Johannes	Huppa	Vienna	Medical University of Vienna	Austria	I do not have any financial interests to declare.
John	SNOWDEN	Sheffield	Sheffield Teaching Hospitals NHS Foundation Trust	United Kingdom	Consultancy for Jazz, Vertex, Medac and IDMC membership for Kiadis
Jose A.	Martinez-Climent	Pamplona	University of Navarra	Spain	Research grants and support from Roche, Genentech, BMS, AstraZeneca, Palleon, Priothera
Julia	Ruiz	Madrid	Niño Jesús Children's Hospital	Spain	none
Jürgen	Kuball	Utrecht	University Medical Center Utrecht	The Netherlands	funding from Novartis, Miltenyi Biotech and Gadeta. JShareholder of Gadeta and hold multiple patents in the field of gdTCR and CAR engineering.
Kai Dannebom	Rejeski	New York / Munich	MSKCC / LMU Munich	USA / Germany	Kite/Gilead: Research Funding and travel support; Novartis: Honoraria; BMS/Celgene: Consultancy, Honoraria; Pierre-Fabre: travel support.
Karl	Petri	Wuerzburg	University Hospital Wuerzburg	Germany	I have a financial interest in SeQure Dx.
Koray	Yalcin	Istanbul	Bahcesehir University Goztepe Medical Park Hospital Pediatric Hematopoietic Stem Cell Transplantation Unit, Acibadem University, Institute of Health Science, Medical Biotechnology, Acibadem Labcell Cellular Therapy Center	Türkiye	Nothing to disclose
Kristin	Reiche	Leipzig	Fraunhofer IZI	Germany	none
Lorna	Warwick	Mississauga	Lymphoma Coalition	Canada	none
Mairead	NiChonghaile	Dublin	St James's Hospital	Ireland	none
Marco	Ruella	Philadelphia	University of Pennsylvania	United States of America	Inventor: CART technologies, Univ. of Pennsylvania, partly licensed to Novartis, Tmunity and viTToria biotherapeutics Research Funding: AbClon, Beckman-Coulter, ONI, Lumicks, ORFLO, GLG, Guidepoint Consultancy/Honoraria: nanoString Advisory Board: AbClon, BMS, Sana, GSK, Bayer, viTToria bio Scientific Founder: viTToria biotherapeutics
Maria	Themeli	Amsterdam	Amsterdam University Medical Centers	Netherlands	I have received research support from Kite-Gilead, consultancy compensation from Sangamo Therapeutics and I am inventor of licensed patents and patent applications related to the development of CARs and CAR-T cells from iPSC.
Maria Chiara	Bonini	Milan	IRCCS Ospedale San Raffaele	Italy	Alia Therapeutics (Adv. Board); Genyo (Adv. Board); Pan Cancer (Adv. Board); Smart Immune (Adv. Board); Intellia therapeutics (Research support; Adv. Board)
Maria-Victoria	Mateos	Salamanca	University Hospital of Salamanca	Spain	Honoraria derived from lectures and participation in advisory boards from Janssen, Celgene-BMS, Takeda, Amgen, GSK, AbbVie, Pfizer, Regeneron, Roche, Sanofi, Steamline
Marie Jose	Kersten	Amsterdam	Amsterdam UMC	Netherlands	Research funding from Kite/Gilead, honoraria for international advisory boards or presentations and travel support from Kite/Gilead, Novartis, BMS, Roche, Adicet Bio, Miltenyi Biotech, Mustang Bio, Abbvie (all to institution)
Marina	Coronado	Madrid	(en blanco)	Spain	(en blanco)
Marjola	Gjergji	Roma	Ospedale pediatrico Bambino Gesù	Italy	No one
Martina	Schuessler-Lenz	Langen	Paul-Ehrlich-Institut	Germany	none
	Spalt	Vienna	General Hospital/University Hospital Vienna	Austria	I have no disclosures
Matteo	Doglio	Milan	San Raffaele Hospital	Italy	no disclosures
Mette D.	Hazenberg	Amsterdam	Amsterdam University Medical Centers	The Netherlands	My husband holds a patent on Nirsevimab (Beyfortus)
Michael	Hudecek	Würzburg	Universitätsklinikum Würzburg	Germany	keine
Michel	Sadelain	New York	Memorial Sloan Kettering Cancer Center	United States of America	The Sadelain lab has collaborative research agreements with Fate Therapeutics, Takeda Pharmaceuticals and Atara Biotherapeutics. Memorial Sloan Kettering Cancer Center has licensed Sadelain lab CAR technologies to Juno/Celgene/BMS, Takeda Pharmaceuticals, Fate Therapeutics, Atara Biotherapeutics, Abintus, Minerva Biotechnologies and Mnemo Therapeutics.
michelle	kenyon	London	King's College Hospital NHS Foundation Trust	United Kingdom	Jazz, Sanofi, pfizer
Miguel-Angel	Perales	New York	Memorial Sloan Kettering Cancer Center	United States of America	Dr. Perales reports honoraria from Adicet, Allogene, Allovir, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, ImmPACT Bio, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotech, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Sanofi, Syncopation, VectivBio AG, and Vor Biopharma. He serves on DSMBs for Cidara Therapeutics and Sellas Life Sciences, and the scientific advisory board of NexImmune. He has ownership interests in NexImmune, Omeros and OrcaBio. He has received institutional research support for clinical trials from Allogene, Incyte, Kite/Gilead, Miltenyi Biotech, Nektar Therapeutics, and Novartis.

First Name	Last Name	City	Hospital / University	Country	Disclosures
Monica	Casucci	Milano	IRCCS San Raffaele Scientific Institute	Italia	(en blanco)
Natacha	Bolanos	Madrid	Lymphoma Coalition	Spain	no personal disclosures
Nicolaus	Kröger	Hamburg	University Medical Center Hamburg	Germany	no COI
Nieves	Cuenca	Madrid	Fundación Leucemia y Linfoma	Spain	Session: NG5 Aftercare; February 16, 2024, 14:35 – 16:05h CET / Caregiver and Patient
Nina	Worel	Vienna	Medical University Vienna	Austria	none
Pere	Barba	Barcelona	Vall d'Hebron University Hospital	Spain	Allogene, Amgen, BMS/Celgene, Kite/Gilead, Incyte, Jazz Pharmaceuticals, Miltenyi Biomedicine, Novartis, Nektar, Pfizer and Pierre Fabre
Pietro	Genovese	Boston	Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Harvard Medical School	United States of America	none
Raffaella	Greco	Milano	IRCCS San Raffaele Hospital	Italy	RG declares: -Speaker honoraria for educational events from Biotest, Pfizer, Medac, Qiagen and Magenta; -Honoraria for advisory board from Pfizer; -No profit-organization: EBMT (Chair ADWP 20-24, Scientific Council Representative with Education Portfolio 22-24).
Rakesh Batuklal	Popat	London	University College London Hospitals NHS Foundation Trust	United Kingdom	Honoraria: Janssen, BMS, Abbvie, Pfizer, GSK, Galapagos; Travel support: Janssen, GSK; Consultancy: GSK, Regeneron
Rashmi	Choudhary	Cambridge	Takeda Pharmaceuticals	United States of America	No part of this talk is a paid or unpaid endorsement for, or criticism against, anyone's technology or medicine. These are my personal opinions and do not represent a judgement of adversity, marketability or limitation of any therapeutic or modality. These are not the opinions of Takeda or any other organization.
Robbie	Majzner	Boston	Dana Farber Cancer Institute	United States of America	Co-founder of CARGO Therapeutics and Link Cell Therapies. Multiple consulting agreements in the field of cancer immunotherapy.
Ruth	Clout	Manchester	The Christie Hospital	United Kingdom	(en blanco)
Sabine Marion	Subklewe	Munich	LMU University Hospital Munich	Germany	Research Support: Amgen, BMS/Celgene, Gilead/Kite, Janssen, Miltenyi Biotec, Molecular Partners, Novartis, Roche, Seagen, Takeda Speakers' Bureau: AstraZeneca, BMS, Gilead/Kite, GSK, Janssen, LAWG, Novartis, Pfizer, Roche, Springer Healthcare Consulting/ Scientific Advisory Bd.: AbbVie, Amgen, Autolus, AvenCell, BMS, CanCell Therapeutics, Genmab US, Gilead, Ichnos Sciences, Incyte Biosciences, Interius BioTherapeutics, Janssen, Miltenyi Biomedicine, Molecular Partners, Nektar Therapeutics, Novartis, Orbital Therapeutics, Pfizer, Roche, Sanofi, Scare, Takeda Travel Support: Gilead, Pfizer, Roche
Sarah	Tettamanti	Monza	Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza	Italia	Nothing to disclose
Scott	Wagers	Maasmechelen	BioSci Consulting	Belgium	Funded partner in the T2EVOLVE project
Solène	Clavreul	Residence city = Nantes / MPE city = Brussels	Myeloma Patients Europe	Residence country = France / MPE country = Belgium	Personal disclosures: none / MPE disclosures: https://www.mpeurope.org/about-mpe/funding-sources/
Sonia	Guedan Carrio	Barcelona	IDIBAPS	Spain	SG is an inventor on patents related to CAR-T cell therapy, filed by the University of Pennsylvania and licensed to Novartis and Tmunity Therapeutics, and has received commercial research funding from Gilead.
Stanley	Riddell	Seattle	Fred Hutchinson Cancer Center	United States of America	Dr. Riddell was a founder, has served as an advisor, and has patents licensed to Juno Therapeutics; is a founder of and holds equity in Lyell Immunopharma; and has served on the advisory boards for Adaptive Biotechnologies and Nohla.
Stefanie	Kreutmair	Zurich	University Hospital Zurich	Switzerland	-
Stephen	Goldrick	London	University College London	United Kingdom	none
Thomas	Jezequel	Nantes	University Hospital of Nantes	France	Lecture/ Speaker for Jazz Pharmaceuticals
Thorsten	Schmidt	Kiel	University Cancer Center Schleswig-Holstein	Germany	none
Tom	van Meerten	Groningen	University Medical Center Groningen	The Netherlands	Research support: Genentech, BMS/Celgene, Siemens Advisory board/honoraria/travel grants: Kite/Gilead, Celgene/BMS, Janssen, Lilly, Takeda
Ulrich	Jaeger	Vienna	Medical University of Vienna	Austria	Consultancy: Novartis, Kite/Gilead; Honoraria and Advisory Boards: Abbvie, BMS, Gilead, Janssen, Miltenyi, Novartis, Roche
Ulrike Gertrud	Köhl	Leipzig	Fraunhofer Institute for Cell Therapy and Immunology	Germany	Research supports: Miltenyi Biotec GmbH; Novartis AG. Consultant/ SABS: Affirmed GmbH; Astra zeneca GmbH; ATMPS Ltd.; Gamma Delta Therapeutics Ltd.; Glycostem Therapeutics; Zellluna Immunotherapy; Vita34 AG.
Valentín	Ortiz-Maldonado	Barcelona	Hospital Clínic de Barcelona	Spain	Research grants: Fundación Española de Hematología y Hemoterapia Travel grants: Kite, BMS, Novartis, Roche, Takeda & Janssen Consultant or advisory fees: Kite, BMS, Novartis, Miltenyi, Janssen & Pfizer Honoraria: Kite, BMS & Janssen Employment: Hospital Clínic de Barcelona

First Name	Last Name	City	Hospital / University	Country	Disclosures
Vanderson Geraldo	Rocha	São Paulo	University of Sao Paulo	Brasil	none
Victoria	Metaxa	London	King's College Hospital	United Kingdom	Speaker fees from Kite/ Gilead
WASEEM	QASIM	London	GREAT ORMOND STREET HOSPITAL & UCL	United Kingdom	Consultancies: Virocell, Wugen, Tessa, Galapagos
Yvonne Yu-Hsuan	Chen	Los Angeles	University of California, Los Angeles	United States of America	Y.Y.C. holds several patent applications in the area of CAR-T cell therapy. Y.Y.C. is a founder of, holds equity in, and receives consulting fees from ImmPACT Bio. Y.Y.C. is a member of the scientific advisory board of and holds equity in Catamaran Bio, Notch Therapeutics, Pluto Immunotherapeutics, Prime Medicine, Sonoma Biotherapeutics, and Waypoint Bio.